LGNXZ.US Ligand Pharms Glucagon
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- 0.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LGNXZ.US undervalued?
Graham numberThe Graham number of Ligand Pharms Glucagon cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ligand Pharms Glucagon fundamental analysis
No fundamental analysis for Ligand Pharms Glucagon yet.
Ligand Pharms Glucagon stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ligand Pharms Glucagon
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma…
Full company profileLigand Pharms Glucagon financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ligand Pharms Glucagon annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 109M | 141M | 251M | 120M | 164M | 242M | 196M | 131M | 167M | 268M | 259M |
| Gross Profit | 103M | 136M | 251M | 120M | 133M | 179M | 143M | 96.3M | 156M | 261M | 248M |
| Operating Income | 43.9M | 68.1M | 164M | 807M | 37.5M | 104M | 3.04M | 11.9M | -22.6M | 47.2M | 13.6M |
| EBITDA | 43.9M | 68.1M | 164M | 807M | 56.7M | 143M | 81.2M | 101M | 40.8M | 193M | 18.8M |
| Net Income | 18.3M | 102M | 143M | 629M | -2.99M | 57.1M | -33.4M | 52.2M | -4.03M | 124M | 8.90M |
| EPS | 0.88 | 4.34 | 5.96 | 32 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 | 6.13 | 0.45 |
| Balance Sheet | |||||||||||
| Total Assets | 602M | 671M | 1.26B | 1.49B | 1.36B | 1.30B | 763M | 787M | 942M | 1.56B | 2.24B |
| Total Liabilities | 231M | 252M | 700M | 728M | 653M | 476M | 165M | 86.3M | 111M | 543M | 1.28B |
| Shareholders' Equity | 371M | 419M | 561M | 767M | 710M | 821M | 597M | 701M | 830M | 1.02B | 962M |
| Cash & Short-term Investments | 141M | 202M | 765M | 1.07B | 411M | 341M | 212M | 170M | 256M | 734M | 447M |
| Total Debt | 213M | 225M | 636M | 650M | 456M | 324M | 87.7M | 6.17M | 7.11M | 451M | 1.15B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 63.0M | 93.6M | 194M | -29.3M | 54.6M | 78.8M | 138M | 49.6M | 97.0M | 49.4M | 60.2M |
| Capital Expenditure | 28.3M | 7.15M | 11.9M | 2.55M | 4.46M | 8.76M | 17.9M | 53.8M | 19.6M | 452K | 528K |
| Free Cash Flow | 34.7M | 86.4M | 182M | -31.9M | 50.1M | 70.0M | 120M | -4.27M | 77.4M | 48.9M | 59.6M |
| Ratios | |||||||||||
| ROE | 4.9% | 24.3% | 25.6% | 82.0% | -0.4% | 7.0% | -5.6% | 7.4% | -0.5% | 12.2% | 0.9% |
| ROA | 3.0% | 15.2% | 11.4% | 42.1% | -0.2% | 4.4% | -4.4% | 6.6% | -0.4% | 8.0% | 0.4% |
| Net Profit Margin | 16.8% | 72.2% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% | 3.4% |
| Debt to Equity | 0.57x | 0.54x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x | 0.44x | 1.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ligand Pharms Glucagon dividends
Ligand Pharms Glucagon has not paid dividends in the last 9 fiscal years.
Who owns Ligand Pharms Glucagon
Ownership data of Ligand Pharms Glucagon is not available yet.
Ligand Pharms Glucagon company profile
- Company name
- Ligand Pharms Glucagon
- Ticker
- LGNXZ.US
- Exchange
- USA Stocks
- Sector
- -
- Industry
- -
- Employees
- 47
- Fiscal year end
- December
- Address
- 555 Heritage Drive, Jupiter, FL, United States, 33458
- Phone
- 858 550 7500
- Website
- ligand.com
About Ligand Pharms Glucagon
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Ligand Pharms Glucagon management
10- Mr. Todd C. Davis Ph.D.CEO & Director · born 1961
- Mr. Octavio EspinozaChief Financial Officer · born 1971
- Mr. Andrew T. Reardon J.D.Chief Legal Officer & Secretary · born 1975
- Mr. Paul J. HaddenSenior Vice President of Investments & Business Development
- Ms. Melanie J. Herman CPAExecutive Director of Investor Relations and Financial Planning & Analysis · born 1979
- Ms. Marjorie FackovecHead of People Operations
- Dr. Keith Marschke Ph.D.Senior Vice President of Biology & Scientific Affairs
- Dr. Vincent D. Antle Ph.D.Senior Vice President of Technical Operations & QA - Capitsol · born 1969
- Dr. Karen R. Reeves M.D.Senior VP of Investments & Head of Clinical Strategy · born 1950
- Mr. Richard B. BaxterSenior VP of Investment Operations · born 1963